Search results for "Hazard"

showing 10 items of 1517 documents

Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as pr…

2018

PURPOSE: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis to adequately stage and treat the patient. Persistent disease after TUR is not uncommon and is why re-TUR is recommended in T1G3 patients. When there is T1 tumor in the re-TUR specimen, very high risks of progression (82%) have been reported. We analyze the risks of recurrence, progression to muscle-invasive disease and cancer-specific mortality (CSM) according to tumor stage at re-TUR in T1G3 patients treated with BCG. METHODS: In our retrospective cohort of 2451 T1G3 patients, 934 patients (38.1%) underwent re-TUR. 667 patients had residual disease (7…

NephrologyMalemedicine.medical_treatment030232 urology & nephrologyNon-muscle invasive bladder cancer · Re-transurethral resection of the bladder · Recurrence · ProgressionSettore MED/24 - Urologia0302 clinical medicineRetrospective StudieRe-transurethral resection of the bladderRecurrenceImmunologicCause of DeathCumulative incidenceStage (cooking)Cause of deathProgressionIntravesicalAdministration IntravesicalLocal030220 oncology & carcinogenesisAdministrationBCG VaccineDisease ProgressionFemaleNon-muscle invasive bladder cancerHumanReoperationmedicine.medical_specialtyUrologyUrologyCystectomyArticleFollow-Up StudieCystectomy03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]medicineHumansAdjuvantsAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesBladder cancerProportional hazards modelbusiness.industryNon-muscle invasive bladder cancer; Progression; Re-transurethral resection of the bladder; Recurrence; Adjuvants Immunologic; Administration Intravesical; Aged; BCG Vaccine; Cause of Death; Cystectomy; Disease Progression; Female; Follow-Up Studies; Humans; Male; Neoplasm Recurrence Local; Neoplasm Staging; Proportional Hazards Models; Reoperation; Retrospective Studies; Urinary Bladder NeoplasmsRetrospective cohort studymedicine.diseaseNeoplasm RecurrenceUrinary Bladder NeoplasmsProportional Hazards ModelNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Tri…

2021

This article belongs to the Collection The Biomarkers for the Diagnosis and Prognosis in Cancer.

Neuroblastoma RAS viral oncogene homologOncologyCancer Researchgenetic riskMyeloid neoplasialeukemic cells0302 clinical medicinecytarabineclinical trials and observations:Other subheadings::/diagnosis [Other subheadings]MedicineComplete remissionazacytidineolder adultsRC254-282variantsLeukemiaAzacytidineHazard ratioleukemiaVariantsCytarabineacute:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Myeloid::Leukemia Myeloid Acute [DISEASES]Neoplasms. Tumors. Oncology. Including cancer and carcinogensMyeloid leukemiaFludarabineLeukemiaOncology030220 oncology & carcinogenesisNGSOlder adultsLeucèmia mieloide aguda - Tractamentmyeloid neoplasiaMyelocyticmedicine.drugmedicine.medical_specialtymyelocyticcomplete remission:Otros calificadores::/diagnóstico [Otros calificadores]Subgroup analysisLeukemic cellsAcutePrognostic factorsArticle:neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mieloide aguda [ENFERMEDADES]03 medical and health sciencesInternal medicineGenetic riskbusiness.industryprognostic factors:diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Odds ratio:Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]medicine.diseaseAvaluació de resultats (Assistència sanitària)CytarabinebusinessClinical trials and observations030215 immunology
researchProduct

Development of a nutritional HACCP plan.

2002

Nutrition and DieteticsFood HandlingDecision TreesDecision treeFood ServicesFood ContaminationPlan (drawing)Risk AssessmentFood handlingUnited StatesSoftware DesignSoftware designHumansFood serviceBusinessRisk assessmentEnvironmental planningFood ScienceFood contaminantProportional Hazards ModelsJournal of the American Dietetic Association
researchProduct

Alcohol and early mortality (before 65 years) in the ‘Seguimiento Universidad de Navarra’ (SUN) cohort: does any level reduce mortality?

2021

AbstractThe aim of this study was to assess the association between alcohol intake and premature mortality (younger than 65 years) and to explore the effect of potential alcohol underreporting by heavy drinkers. We followed-up 20 272 university graduates. Four categories of alcohol intake were considered (abstainer, light, moderate and heavy consumption). Repeated measurements of alcohol intake and updated information on confounders were used in time-dependent Cox models. Potential underreporting of alcohol intake by some heavy drinkers (likely misclassified as light or moderate drinkers) was explicitly addressed in an attempt to correct potential underreporting by using indirect informatio…

Nutrition and Dieteticsbusiness.industryProportional hazards modelConfoundingHazard ratioMedicine (miscellaneous)Confidence intervalInterquartile rangeCohortMedicineInformation biasbusinessProspective cohort studyDemographyBritish Journal of Nutrition
researchProduct

Impacts of volcanic hazards on rural communities and adaptative strategies: A case study of the Virunga Volcanic Province (Democratic Republic of Con…

2023

co auteur étranger; International audience; Active volcanoes are a continuous threat for several regions worldwide and cause socio-economic and environmental issues, including the Virunga Volcanic Province (D.R. Congo). There, more than 2 million people are permanently exposed to the hazards of the most active volcanoes in Africa: Nyiragongo and Nyamulagira. However, there is a clear lack of information regarding the impacts of these hazards and how they may be affected by social vulnerability. In this study, a household survey based on semi-structural interviews was performed for rural communities in Virunga. This research aims to (i) investigate the impacts of volcanic hazards on rural co…

NyiragongoSocial vulnerability[SDU.STU.VO]Sciences of the Universe [physics]/Earth Sciences/VolcanologyVolcanic hazardsGeologyBuilding and ConstructionRisks perceptionGeotechnical Engineering and Engineering GeologySafety ResearchNyamulagiraSettore GEO/08 - Geochimica E Vulcanologia
researchProduct

The GiSAS study: Rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatme…

2011

Given the controversy about the comparative efficacy of first- compared with second-generation antipsychotics in the treatment of schizophrenia, more large-scale evidence is needed to guide clinicians in their prescriptions. Most randomized controlled trials (RCTs) were conducted in centers of excellence on highly selected samples, poorly representative of real-world patients, and often suffered conflicts of interest as they were sponsored by drug companies. The primary aim of the present study is to compare the effectiveness of haloperidol, olanzapine and aripiprazole in a representative sample of schizophrenia patients. The GiSAS trial is an open-label, independent, pragmatic RCT in Itali…

Olanzapinemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAripiprazoleQuinolonesPragmatic trialPiperazineslaw.inventionAntipsychoticBenzodiazepinesRandomized controlled triallawAntipsychotic; Pragmatic trial; SchizophreniamedicineClinical endpointHumansPharmacology (medical)AntipsychoticPsychiatrySettore MED/25 - PsichiatriaProportional Hazards Modelsbusiness.industryPatient SelectionGeneral MedicineDiscontinuationLogistic ModelsItalyTolerabilityOlanzapineResearch DesignSchizophreniaPhysical therapyHaloperidolObservational studyAripiprazoleantipsychotic schizophrenia metabolic syndromebusinessAntipsychotic Agentsmedicine.drugContemporary Clinical Trials
researchProduct

The humoral immune system has a key prognostic impact in node-negative breast cancer.

2008

Abstract Estrogen receptor (ER) expression and proliferative activity are established prognostic factors in breast cancer. In a search for additional prognostic motifs, we analyzed the gene expression patterns of 200 tumors of patients who were not treated by systemic therapy after surgery using a discovery approach. After performing hierarchical cluster analysis, we identified coregulated genes related to the biological process of proliferation, steroid hormone receptor expression, as well as B-cell and T-cell infiltration. We calculated metagenes as a surrogate for all genes contained within a particular cluster and visualized the relative expression in relation to time to metastasis with…

OncologyAdultCancer Researchmedicine.medical_specialtyMultivariate analysisEstrogen receptorBreast NeoplasmsMetastasisCohort StudiesBreast cancerImmune systemInternal medicineMedicineCluster AnalysisHumansAgedCell ProliferationOligonucleotide Array Sequence AnalysisAged 80 and overbusiness.industryProportional hazards modelGene Expression ProfilingHazard ratioCarcinomaMiddle Agedmedicine.diseasePrognosisGene Expression Regulation NeoplasticOncologyNeutrophil InfiltrationLymphatic MetastasisCohortImmunologyAntibody FormationFemaleLymph NodesbusinessGenes NeoplasmCancer research
researchProduct

HER2 amplification in recurrent breast cancer following breast-conserving therapy correlates with distant metastasis and poor survival.

2005

The authors analyzed the HER2 status in early-stage nonrecurrent and recurrent breast cancer groups following breast-conserving treatment. Retrospective analyses of a group of 36 invasive early breast cancer (IBC) patients who developed a local recurrence as a first event and of a random control group of 69 IBC patients were made. HER2 status was assessed by the HercepTest and fluorescence in situ hybridization. The Kaplan-Meier proportional log-rank test was used to study the impact of the biological factors on the metastasis-free interval (MFI) and the overall survival (OS). The Cox proportional hazards model, using stepwise selection was performed to identify the independent predictors o…

OncologyAdultCancer Researchmedicine.medical_specialtymedicine.medical_treatmentBreast NeoplasmsMastectomy SegmentalMetastasisBreast cancerTrastuzumabPredictive Value of TestsInternal medicinemedicineHumansNeoplasm Metastasisskin and connective tissue diseasesSurvival analysisIn Situ Hybridization FluorescenceAgedGynecologyProportional hazards modelbusiness.industryGene AmplificationGenes erbB-2Middle Agedmedicine.diseasePrognosisSurvival AnalysisOncologyPredictive value of testsFemaleNeoplasm Recurrence LocalbusinessBreast carcinomaMastectomymedicine.drugInternational journal of cancer
researchProduct

Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy

2010

Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients eligible for second-line treatment is scarce. The aim of this study was to assess the prognostic role of a number of routinely collected clinical variables and to provide a summary index to discriminate patients according to probability of survival.Methods: individual data from nine randomised trials of second-line treatment in advanced NSCLC were analysed. Primary end-point was overall survival (OS). Cox model, stratified by trial, was used for multivariate analyses, and a prognostic index was provided and validated according to an internal/external procedure.Results: Out of 1239 patients, 119…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisLung NeoplasmsWEEKLY DOCETAXELIRINOTECANCOMBINATION CHEMOTHERAPYAntineoplastic AgentsERLOTINIBPrognostic factorsNSCLCTHERAPYPooled analysisPLUS GEMCITABINEInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansStage (cooking)Lung cancerEVERY 3 WEEKSAgedNeoplasm StagingRandomized Controlled Trials as TopicAged 80 and overPerformance statusProportional hazards modelbusiness.industryAge FactorsCombination chemotherapyPHASE-III TRIALMiddle Agedmedicine.diseasePrognosisTreatment OutcomeOncologyMeta-analysisPrognostic scoreCOMPARING DOCETAXELSecond-line treatmentAdenocarcinomaFemalebusinessEpidemiologic MethodsNon-small-cell lung cancerEuropean Journal of Cancer
researchProduct

Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised pros…

2008

Platinum/taxane combinations are widely used in patients with carcinoma of unknown primary (CUP), yielding response rates of 30% and median overall survival of 9-11 months in selected patients. Yet these combinations have not been subject to a randomised trial to overcome selection bias, a major problem in CUP. We randomised 92 patients to either paclitaxel/carboplatin (arm A) or the non-platinum non-taxane regimen gemcitabine/vinorelbine (arm B). The primary endpoint was rate of practicability as defined: application of >or=2 cycles of therapy (1) with a maximal delay of 1 week (2) and survival of >or=8 months (3). Practicability was shown in 52.4% (95% CI 36-68%) in arm A and in 42.2% (95…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyPaclitaxelmedicine.medical_treatmentneoplasmsVinorelbineVinblastineDeoxycytidineCarboplatinchemistry.chemical_compoundInternal medicineAntineoplastic Combined Chemotherapy ProtocolsClinical StudiesmedicineClinical endpointHumansProspective StudiesAgedProportional Hazards ModelsChemotherapyTaxaneclinical trial phase IIbusiness.industryVinorelbineMiddle AgedGemcitabinemedical oncologyGemcitabineCarboplatinSurgeryErbB ReceptorsRegimenOncologyDocetaxelchemistryrandomized controlled trialunknown primaryNeoplasms Unknown Primaryanti-neoplastic-combined chemotherapy protocolsFemalebusinessmedicine.drugBritish journal of cancer
researchProduct